Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $60.55.

Several research analysts have recently weighed in on the stock. Loop Capital decreased their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Piper Sandler restated a “neutral” rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. William Blair reiterated a “market perform” rating on shares of Tempus AI in a research note on Tuesday. Finally, Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $59.10 on Wednesday. Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The company has a fifty day moving average price of $51.28 and a 200 day moving average price of $52.17.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 84,640 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $80.87, for a total transaction of $6,844,836.80. Following the sale, the chief executive officer now owns 4,964,820 shares of the company’s stock, valued at $401,504,993.40. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,583,467 shares of company stock valued at $130,542,311.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TEM. Operose Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at $25,000. First Horizon Advisors Inc. acquired a new position in Tempus AI during the third quarter valued at $30,000. Farther Finance Advisors LLC purchased a new stake in Tempus AI in the 4th quarter worth about $34,000. Prestige Wealth Management Group LLC boosted its position in Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after acquiring an additional 965 shares during the period. Finally, NewEdge Advisors LLC purchased a new position in Tempus AI during the 4th quarter valued at about $49,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.